Genzyme's Synvisc retains high reimbursement rate
238851
Genzyme Corp.  said on Friday  its osteoarthritis pain treatment Synvisc will retain a  separate, higher reimbursement rate, after the U.S. government  reversed its earlier decision to cut the rate, sending Genzyme  shares higher.
200045
THE REGION Study: Uninsured pay highest drug prices
725261
There's encouraging news about an enzyme replacement drug.
156850
Fifteen months ago, Genzyme Corp. and Transkaryotic Therapies Inc. of Cambridge decided to kiss and make up. It didn't last.
618409
In a surprise attempt by a Cambridge biotechnology company to trump a takeover bid by one of its neighbors, Millennium Pharmaceuticals Inc. yesterday said it had reached a $515 million deal to buy a small Canadian drug firm that Genzyme Corp. has been trying to buy since late last month.
482130
By Dale Kasler, The Sacramento Bee, Calif.  Feb. 7--GenCorp Inc. said Tuesday it has received a $29.7 million payment from the company that bought its chemical business in 2005.
317406
In an unusual hostile takeover attempt, Genzyme Corp. yesterday went public with a $380 million cash offer to buy a Canadian drug-development company whose board of directors has twice rejected the bid.
28028
Genzyme Corp.&#39;s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug
204544
Will Genzyme's Campath get approval?
359683
A Johnson & Johnson JNJ.N  promotion for rheumatoid arthritis drug Remicade is misleading  because it makes unsupported claims about the drug's  effectiveness and omits important information about risks, U.S.  regulators said in a letter released on Monday.
225873
For people in the beginning stages of rheumatoid arthritis but who have a poor prognosis, early treatment with the drug Remicade can pay dividends, according to the results of a small study.
555063
NEW YORK  - Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the US Food and Drug Administration (news - web sites) (FDA (news - web sites)) for the treatment of
451993
Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
594161
Genzyme announces positive study results with a recently acquired drug.
646800
Gaithersburg-based GenVec has run into a problem with its top drug candidate, and investors have had an adverse reaction. GenVec says the US Food and Drug Administration has requested that clinical trials
646040
A heart treatment from Canadian   biotech firm Vasogen Inc., which failed a key clinical trial   hurdle in June, still helped more than 70 percent of patients,   researchers said on Sunday.
189561
US regulators said Tuesday they approved a new cancer drug from Genzyme Corp. for treating a type of childhood leukemia. The Food and Drug Administration, in a statement on its